BFRIW
Biofrontera Inc.Warrants of Biofrontera Inc. · BFRI stock page →
—
Market cap
$74.3K
Nano cap
1 year
−23.5%
from $1.02 · Oct 27
30 days
−30.6%
from $1.13
52-week range
$0.5700–1.61
−51% from high · low Dec 31
Avg volume 20D
251.7K
Oct 5 spike 720.9K
Short interest
2.7K
≈0.0% of shares · −25.0%
Days to cover
1.1
at average volume
New fund stakes
0
Q1 2025 13F · 0 exits
Filing reports
1
analyzed by SecBot
SecBot read MIXED 1 report · latest
Balance 0 bearish · 0 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 1/1
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- X Jul 15 Short interest jumps 31.0% to 6.4K
- X Jul 31 Short interest falls 60.0% to 2.6K
- X Aug 31 Short interest jumps 77.3% to 5.3K
- X Sep 15 Short interest falls 31.7% to 3.6K
- X Sep 30 Short interest falls 25.0% to 2.7K
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q1 2025: 0 added (0 new), 1 trimmed or exited.
- Short sellersCOVERING
Short interest −25.0% to 2.7K shares. 1.1 days to cover, ≈0.0% of shares.
- TrendDOWNTREND
34% below its 50-day average.
Who's buying
13F· Q1 20250
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| UBS Group AG | TRIM | $54.00 |
| UBS Group AG | TRIM | $154.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
May 21, 2026
Company news
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company…
May 14, 2026
Earnings
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the…
May 8, 2026
Earnings
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company…
Mar 19, 2026
Earnings
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Conference call will be held today, Thursday, March 19 at 10:00 am ET
Mar 9, 2026
Earnings
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company…
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $8.3M |
| Next Q | — | — | — | $15.8M |
| Current FY | — | — | — | $46.1M |
| Next FY | — | — | — | $53.5M |
Short side
FINRA· Sep 30, 20262,701
shares short
-25.0%
vs prior settlement
1.1
days to cover
≈0.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
May 21, 2026 Routine
May 14, 2026 SEC Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or th
Biofrontera Inc. reported Q1 2026 revenue of $10.1M, up ~17% YoY from $8.6M, but slightly below the $10.3M consensus…
8-K — Impact 5/10
Mar 31, 2025 Inst.
UBS Group AG — TRIM
891 shares ($54.00)
Dec 31, 2024 Inst.
UBS Group AG — TRIM
2,519 shares ($154.00)
SecBot reports
1 filing · 0 bullish · 0 bearish · 1 mixedAll BFRIW filing & press-release reports (1)
- 8-K reportMay 14, 2026